181871-73-8

Basic information

• Product Name: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER
• Synonyms: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER;METHYL 4-METHOXY-2-NITROBENZOATE;Benzoic acid, 4-Methoxy-2-nitro-, Methyl ester
• CAS NO: 181871-73-8
• Molecular Formula: C9H9NO5
• Molecular Weight: 211.17
• Product Categories: blocks;Carboxes
• Mol File: 181871-73-8.mol

Chemical Properties

• Boiling Point: 336 °C at 760 mmHg
• Flash Point: 158.5 °C
• Appearance: /
• Density: 1.294 g/cm³
• Vapor Pressure: 0.000116mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(181871-73-8)
• EPA Substance Registry System: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(181871-73-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 181871-73-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Methoxy-2-nitro-benzoic acid methyl ester is used as a building block for the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the development of new drugs and medications.
Used in Chemical Industry:
In the chemical industry, 4-Methoxy-2-nitro-benzoic acid methyl ester is used in the synthesis of various organic compounds. Its reactivity and solubility in organic solvents make it a valuable intermediate in the production of different chemical products.
Safety Precautions:
It is important to handle 4-Methoxy-2-nitro-benzoic acid methyl ester with caution, as it may be harmful if ingested or inhaled. Additionally, it may cause skin and eye irritation. Proper safety measures, such as wearing protective clothing and using appropriate handling equipment, should be taken to minimize the risk of exposure.

InChI:InChI=1/C9H9NO5/c1-14-6-3-4-7(9(11)15-2)8(5-6)10(12)13/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 33844-21-2 2-nitro-4-methoxybenzoic acid 
• 74-88-4 methyl iodide 
• 158580-57-5 methyl 4-bromo-2-nitrobenzoate 

Downstream Products

• 1221497-10-4 2-amino-4-methoxybenzhydrazide 

Relevant articles and documents

Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain

The unique role of fatty acid amide hydrolase (FAAH) in terminating endocannabinoid (EC) signaling supports its relevance as a therapeutic target. Inhibition of EC metabolizing enzymes elicits indirect agonism of cannabinoid receptors (CBRs) and therapeutic efficacy devoid of psychotropic effects. Based on our previous ligands, and aiming at the discovery of new selective FAAH inhibitors, we developed a series of 12 new compounds characterized by functionalized tricyclic scaffolds. All the developed compounds display negligible activity on monoacylglycerol lipase (MAGL) and CBRs. The most potent FAAH inhibitors of the newly developed series, 6-oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-6-phenylhexylcarbamate (5 h) and 4-oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-(6-phenylhexyl)carbamate (5 i) (nanomolar FAAH inhibitors, the latter of which also shows micromolar affinity at the CB1R), were selected for further studies. Results of cell-based studies on a neuroblastoma cell line (IMR32) demonstrated 5 h, 5 i, and our reference compound 3 ([3-(3-carbamoylpyrrol-1-yl)phenyl] N-(5-phenylpentyl)carbamate) to lack any cytotoxic effect, while all three showed the ability to decrease oxidative stress by reducing the expression of the redox-sensitive transcription factor NF-κB. Encouraged by these data, these compounds were studied in vivo and were dosed orally in a mouse model of neuropathic pain. At 10 mg kg?1 all the compounds were able to relieve the hypersensitivity induced by oxaliplatin.

5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS

This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of Formula (1) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.